Novadaq Technologies Inc.

Novadaq Technologies Inc.

November 01, 2005 09:00 ET

Novadaq Adds Co-Chief Medical Advisors to Cardiac Team

TORONTO, ONTARIO--(Marketwire - Nov. 1, 2005) - Novadaq® Technologies Inc. (TSX:NDQ), today announced the appointment of T. Bruce Ferguson, M.D. and Peter J. Fitzgerald M.D., Ph.D., as Co-Chief Medical Advisors for the company’s cardiac business. Advisory responsibilities will include assisting in the development and implementation of physician, hospital and payer targeted initiatives that will support Novadaq’s efforts to establish the SPY® System as a standard of care in cardiac surgery.

“We are very pleased to have Dr. Ferguson and Dr. Fitzgerald, two highly respected thought leaders in the field of cardiovascular medicine, join the Novadaq team,” said Dr. Arun Menawat, President and Chief Executive Officer of Novadaq Technologies Inc. “With our expanding presence in cardiac surgery their clinical expertise, commitment to quality procedural outcomes in our target market and in-depth knowledge of imaging and medical technologies will be invaluable. Additionally, their network within the cardiac space will help Novadaq to establish the SPY Intra-operative Imaging System as a standard of care during cardiac surgery.”

Dr. Bruce Ferguson is a Professor of Surgery and Physiology and Chief of Cardiac Surgery at the Louisiana State University School of Medicine and Health Sciences Center in New Orleans. Among other appointments, Dr. Ferguson is a member of the American Association for Thoracic Surgery and the American Heart Association’s Quality of Care and Outcomes Research Expert Panel, Executive Database Steering Committee and Quality of Care and Outcomes Research IWG Steering/Program Committee. He also serves as the Chairman of the Council on Quality, Research and Patient Advocacy for the Society of Thoracic Surgeons, is a member of the Workforce on Clinical Trials, and is Principal Investigator of the Society’s Continuous Quality Improvement grants from AHRQ. He is a member of the editorial board of the Annals of Thoracic Surgery and is an invited reviewer for such respected medical journals as JAMA, Circulation, Journal of Thoracic and Cardiovascular Surgery, American Heart Journal, and Health Affairs. Dr. Ferguson received his M.D. from the Washington University School of Medicine, St. Louis, Missouri.

Dr. Peter Fitzgerald is a Professor of Medicine (Cardiology and Engineering) at the Stanford School of Medicine, where he also serves as Co-Director for the Center for Research in Cardiovascular Interventions. In addition to his 200 peer-reviewed articles and over 160 research contribution articles, Dr. Fitzgerald has also served on the editorial board of several prestigious medical journals including the American College of Cardiology, Catheterization and Cardiovascular Interventions, Endovascular Radiation Therapy Digest, International Journal of Cardiovascular Interventions, Journal of Invasive Cardiology, REMEDICA Intravascular Imaging and Heart, the official journal of the British Cardiac Society. He is a member of the American Heart Association and Fellow of the American College of Cardiology and has served as an advisory board member for Medtronic, Boston Scientific, Guidant and J&J, among others. Dr. Fitzgerald received both his M.D. and Ph.D. in biomedical engineering from the Dartmouth School of Medicine and his residency of cardiology fellowship training at the University of California, San Francisco.

About Novadaq Technologies

Novadaq Technologies (TSX:NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY Intra-operative Imaging System enables surgeons to visually assess coronary vasculature and bypass graft functionality during the course of cardiac surgery. Novadaq's ophthalmic product, the OPTTX™ System, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. The OPTTX System is currently being evaluated in clinical trials.

For more information, please visit the company's website at

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings, actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information